The functional neuroanatomy of the placebo effect

American Journal of Psychiatry

Volumn 159, Issue 5, 2002, Pages 728-737

  Mayberg, Helen S ^a   Silva, J Arturo ^a   Brannan, Steven K ^a   Tekell, Janet L ^a   Mahurin, Roderick K ^a   McGinnis, Scott ^a   Jerabek, Paul A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PLACEBO;

ADULT; ARTICLE; BRAIN; BRAIN STEM; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; INSULA; LIMBIC CORTEX; MALE; NEUROANATOMY; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PREMOTOR CORTEX; PRIORITY JOURNAL; REMISSION; SUBICULUM; THALAMUS;

BRAIN; CEREBRAL CORTEX; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FLUOXETINE; GLUCOSE; HUMANS; LIMBIC SYSTEM; MALE; MIDDLE AGED; PLACEBO EFFECT; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036237860     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.5.728     Document Type: Article

References (98)

1. A historic and heuristic definition of the placebo
2. The placebo effect: Can we use it better?
3. The placebo: Is it much ado about nothing?
4. Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication
5. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the FDA database
6. Validity of clinical trials of antidepressants
7. Can the placebo be the cure?
8. The placebo prescription
9. Placebos: A review of the placebo response
10. What conditions are necessary to assess antidepressant efficacy?
11. Placebo response in depression: Bane of research, boon to therapy
12. The prophylactic efficacy of fluoxetine in unipolar depression
13. Efficacy in long-term treatment of depression
14. Three-year outcomes for maintenance therapies in recurrent depression
15. Use of pattern analysis to predict differential relapse on fluoxetine and placebo during continuation/maintenance treatment
16. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression
17. Reduction of prefrontal cortex glucose metabolism common to three types of depression
18. Glucose utilization in the temporal cortex of affectively ill patients: Positron emission tomography
19. The anatomy of melancholia - Focal abnormalities of cerebral blood flow in major depression
20. A functional anatomical study of unipolar depression
21. Frontal lobe dysfunction in secondary depression
22. Cingulate function in depression: A potential predictor of treatment response
23. Functional brain imaging, limbic function, and affective disorders
24. Left prefrontal glucose hypometabolism in the depressed state: A confirmation
25. Changes in regional cerebral blood flow on recovery from depression
26. Regional cerebral blood flow changes following chronic administration of antidepressant drugs
27. Effect of sertraline on regional metabolic rate in patients with affective disorder
28. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness
29. Regional metabolic effects of fluoxetine in major depression: Serial changes and relationship to clinical response
30. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine
31. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression
32. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex
33. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression
34. The effects of ECT on brain glucose metabolism: A pilot FDG PET study
35. A preliminary study of the effects of electroconvulsive therapy on regional brain glucose metabolism in patients with major depression
36. Decreased regional brain metabolism after ECT
37. The frontal lobes and neurosurgery for psychiatric disorders
38. Changes in prefrontal cortex and paralimbic activity in depression following two weeks of daily left prefrontal TMS
39. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy
40. Eng C Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride
41. Parloff MB (National Institute of Mental Health Treatment of Depression Collaborative Research Program): General effectiveness of treatments
42. Cognitive therapy and pharmacotherapy for depression: Singly and in combination
43. Medications versus cognitive behavior therapy for severely depressed outpatients: Mega-analysis of four randomized comparisons
44. Practice guideline for the treatment of patients with major depressive disorder (revision)
45. Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls
46. Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders
47. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F18)2-fluoro-2-deoxy-D-glucose: Validation of method
48. A default mode of brain function
49. A rating scale for depression
50. Time course of improvement under antidepressant treatment: A survival-analytical approach
51. 15O tissue activity
52. A modality-independent approach to spatial normalization of tomographic images of the human brain
53. A suggestion for using powerful and informative tests of normality
54. Three-dimensional statistical analysis for CBF activation studies in human brain
55. A highly accurate method of localizing regions of neuronal activation in the human brain with positron emission tomography
56. Automated labeling of the human brain: A preliminary report on the development and evaluation of a forward-transform method
57. A new validation of the Hamilton Rating Scale for Depression
58. Initiation and adaptation: A paradigm for understanding psychotropic drug action
59. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders
60. Neural plasticity to stress and antidepressant treatment
61. 3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain
62. In vitro and in vivo characterisation of norbeta-CIT: A potential radioligand for visualisation of the serotonin transporter in the brain
63. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: An in vitro electrophysiologic study in the rat
64. 1A receptors
65. Effect of chronic antidepressant treatment on transcription factor binding activity in rat hippocampus and frontal cortex
66. Effects of acute and chronic treatment with fluoxetine on regional glucose cerebral metabolism in rats: Implications for clinical therapies
67. Influence of ascending serotonergic pathways on glucose use in the conscious rat brain, II: Effects of electrical stimulation of the rostral raphe nuclei
68. Negative thinking in depression: Cause, effect, or reciprocal relationship?
69. A role for volition and attention in the generation of new brain circuits
70. Relationship between dysfunctional cognitions and depressive subtypes
71. How does cognitive therapy work?
72. Emotional processing, three modes of mind and the prevention of relapse in depression
73. Biological and psychological processes in recovery from depression during cognitive therapy
74. Comparison of the effects of cognitive therapy and pharmacotherapy on hopelessness and self-concept
75. Differential cognitive response to a mood challenge following successful cognitive therapy or pharmacotherapy for unipolar depression
76. Motivation and expectancy factors in symptoms perception: A laboratory study of the placebo effect
77. The doctor as therapeutic agent: A placebo effect research agenda
78. Clinical trials of antidepressants: The hidden face: Where locus of control appears to play a key role in depression outcome
79. Specifying nonspecifics: Psychological mechanisms of placebo effects
80. Biological rhythms and depression: The role of zeitgebers and zeitstorers
81. Social zeitgebers and biological rhythms
82. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression
83. Clinical features of depressed patients who do and do not improve with placebo
84. A comparison of placebo responders and nonresponders in subgroups of depressive disorder
85. No gender differences in placebo responses of patients with major depressive disorder
86. Cingulate cortex of the rhesus monkey, II: Cortical afferents
87. Monoamine innervation of cingulate cortex
88. The retrosplenial cortex and emotion: New insights from functional neuroimaging of the human brain
89. Initial recovery patterns may predict which maintenance therapies for depression will keep older adults well
90. The introductory placebo washout: A retrospective evaluation
91. Are placebo run ins justified?
92. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment
93. Limbic-cortical dysregulation: A proposed model of depression